Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Consolidated Net Income fell 3339.64% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 5006.66%. This contributed to the annual value of -$161.3 million for FY2024, which is 33461.64% down from last year.
  • Latest data reveals that Zenas BioPharma reported Consolidated Net Income of -$51.5 million as of Q3 2025, which was down 3339.64% from -$52.2 million recorded in Q2 2025.
  • Zenas BioPharma's Consolidated Net Income's 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$56.5 million in Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median Consolidated Net Income value was -$38.0 million (recorded in 2024), while the average stood at -$31.9 million.
  • Per our database at Business Quant, Zenas BioPharma's Consolidated Net Income crashed by 20837.08% in 2024 and then tumbled by 2076.62% in 2025.
  • Over the past 3 years, Zenas BioPharma's Consolidated Net Income (Quarter) stood at -$24.8 million in 2023, then tumbled by 128.15% to -$56.5 million in 2024, then grew by 8.91% to -$51.5 million in 2025.
  • Its Consolidated Net Income stands at -$51.5 million for Q3 2025, versus -$52.2 million for Q2 2025 and -$33.6 million for Q1 2025.